Skip to Content

Abelcet (amphotericin b lipid complex) Disease Interactions

There are 3 disease interactions with Abelcet (amphotericin b lipid complex):

Moderate

Ampho B lipid complex (applies to Abelcet) anemia

Moderate Potential Hazard, Moderate plausibility.

Amphotericin B lipid complex may depress red blood cell production and occasionally causes a normocytic, normochromic anemia. A 4% incidence was reported during clinical trials. Although the anemia is generally well tolerated and reverses completely after discontinuation of therapy, it may be problematic in patients with preexisting anemia. Therapy with amphotericin B lipid complex should be administered cautiously in anemic patients. Frequent blood counts and hematocrit levels are recommended.

References

  1. "Product Information. Abelcet (amphotericin B)." Liposome Company Inc, The, Princeton, NJ.
Moderate

Ampho B lipid complex (applies to Abelcet) electrolyte disturbances

Moderate Potential Hazard, Low plausibility. Applicable conditions: Hyperkalemia, Hypokalemia, Hypocalcemia, Magnesium Imbalance

Amphotericin B lipid complex is substantially less nephrotoxic than traditional amphotericin B but may still cause hypo- and hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be monitored in all patients receiving therapy with amphotericin B lipid complex but particularly closely in patients with preexisting electrolyte abnormalities. Mineral and electrolyte supplementation may likely be required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances.

References

  1. Kline S, Larsen TA, Fieber L, Fishbach R, Greenwood M, Harris R, Kline MW, Tennican PO, Janoff EN "Limited toxicity of prolonged therapy with high doses of amphotericin b lipid complex." Clin Infect Dis 21 (1995): 1154-8
  2. "Product Information. Abelcet (amphotericin B)." Liposome Company Inc, The, Princeton, NJ.
  3. Oravcova E, Mistrik M, Sakalova A, Drgona L, Kollar T, Helpianska L, Ilavska I, Sorkovska D, Spanik S, Kukuckova E, Krcmery V "Amphotericin b lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients." Chemotherapy 41 (1995): 473-6
Moderate

Ampho B lipid complex (applies to Abelcet) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Amphotericin B lipid complex is substantially less nephrotoxic than traditional amphotericin B but may still cause decreased renal function and abnormalities such as hypo- and hyperkalemia, hypomagnesemia, and renal tubular acidosis. Renal function should be monitored in all patients receiving therapy with amphotericin B lipid complex but particularly closely in patients with preexisting renal impairment. Serum creatinine, BUN, potassium and magnesium levels should be evaluated regularly, and dosing adjusted or discontinued if necessary. Hydration with normal saline may decrease the risk for nephrotoxicity. In addition, administration of alkali medication may help to prevent renal tubular acidosis.

References

  1. Sorkin P, Nagar H, Weinbroum A, Setton A, Israitel E, Scarlatt A, Silbiger A, Rudick V, Kluger Y, Halpern P "Administration of amphotericin b in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients." Crit Care Med 24 (1996): 1311-5
  2. Block ER, Bennett JE, Livoti LG, Klein WJ, Roy R, Henderson L "Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance." Ann Intern Med 80 (1974): 613-7
  3. "Product Information. Abelcet (amphotericin B)." Liposome Company Inc, The, Princeton, NJ.
  4. Gales MA, Gales BJ "Acute renal failure with amphotericin B in lipid emulsion." Ann Pharmacother 30 (1996): 1036
View all 4 references

Abelcet (amphotericin b lipid complex) drug interactions

There are 154 drug interactions with Abelcet (amphotericin b lipid complex)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.